# Acute-on-chronic liver failure: a retrospective review of cases at a transplantation center in Brazil

**Authors:** Fernando Camargo Fernandes, Amanda Pinter Carvalheiro da Silva Boteon, Giovana Garcia Rossi, Fernanda Marques, Bianca Della-Guardia, Yuri Longatto Boteon

PMC · DOI: 10.1590/acb392624 · 2024-06-14

## TL;DR

This study examines acute-on-chronic liver failure in Brazil, finding liver transplantation significantly improves survival, especially for severe cases.

## Contribution

The study provides real-world data on ACLF outcomes and highlights liver transplantation's effectiveness in a Brazilian LT center.

## Key findings

- 35% 28-day mortality rate for ACLF patients, increasing with severity.
- Liver transplantation resulted in 100% 28-day survival for transplanted patients.
- Transplantation significantly improved survival in ACLF-3 cases compared to no transplant.

## Abstract

Acute-on-chronic liver failure (ACLF) is a leading cause of death in cirrhotic patients. This study aims to describe the outcomes of in-patients with ACLF at a liver transplantation (LT) center in Brazil.

Retrospective study analyzing patient data from 2017 to 2022. Re-transplant cases and patients without previous chronic liver disease were excluded. The ACLF diagnosis was based on the European Association for the Study of the Liver-Chronic Liver Failure criteria and assessments repeated on days 3 and 7 after the initial diagnosis.

Among 381 patients, 10.49% (n = 40) were diagnosed with ACLF. Bacterial infection was the most common precipitating factor (45%). Kidney failure occurred in 65% of the cases. The 28-day mortality rate was 35% and varied according to ACLF severity at diagnosis, from single organ failure (ACLF-1) at 22% to three organ failures (ACLF-3) at 60%. Eighteen patients (45%) were transplanted with a 100% 28-day survival rate. For ACLF-3 cases at diagnosis (n = 15), the 28-day and 1-year survival rates with a transplant (n = 4) were 100% and 80%, respectively, and without transplant (n = 11), 10 and 0%, respectively.

ACLF was associated with high mortality rates. LT was an effective therapeutic option, particularly for ACLF-3 cases.

## Linked entities

- **Diseases:** cirrhosis (MONDO:0005155), kidney failure (MONDO:0001106), bacterial infection (MONDO:0005113)

## Full-text entities

- **Diseases:** Kidney failure (MESH:D051437), organ failures (MESH:D009102), ACLF (MESH:D065290), liver disease (MESH:D008107), Bacterial infection (MESH:D001424), of the Liver-Chronic Liver Failure (MESH:D058625), cirrhotic (MESH:D000094724), death (MESH:D003643)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11178148/full.md

---
Source: https://tomesphere.com/paper/PMC11178148